Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Drug Class
1.2.3. Route of Administration
1.2.4. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Inflammatory Bowel Disease Treatment Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.3.1. Phase 1
3.3.3.2. Phase 2
3.3.3.3. Phase 3
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. U.S. Inflammatory Bowel Disease Treatment market: Type Business Analysis
4.1. Type Market Share, 2024 & 2030
4.2. Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
4.4. Crohn's Disease
4.4.1. Crohn's Disease Market, 2018 - 2030 (USD Million)
4.5. Ulcerative Colitis
4.5.1. Ulcerative Colitis Market, 2018 - 2030 (USD Million)
Chapter 5. U.S. Inflammatory Bowel Disease Treatment market: Drug Class Business Analysis
5.1. Drug Class Market Share, 2024 & 2030
5.2. Drug Class Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
5.4. Aminosalicylates
5.4.1. Aminosalicylates Market, 2018 - 2030 (USD Million)
5.5. Corticosteroids
5.5.1. Corticosteroids Market, 2018 - 2030 (USD Million)
5.6. TNF Inhibitors
5.6.1. TNF Inhibitors Market, 2018 - 2030 (USD Million)
5.7. IL inhibitors
5.7.1. IL inhibitors Market, 2018 - 2030 (USD Million)
5.8. Anti-integrin
5.8.1. Anti-integrinMarket, 2018 - 2030 (USD Million)
5.9. JAK inhibitors
5.9.1. JAK inhibitors Market, 2018 - 2030 (USD Million)
5.10. Others
5.10.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. U.S. Inflammatory Bowel Disease Treatment market: Route of Administration Business Analysis
6.1. Route of Administration Market Share, 2024 & 2030
6.2. Route of Administration Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
6.4. Oral
6.4.1. Oral Market, 2018 - 2030 (USD Million)
6.5. Injectable
6.5.1. Injectable Market, 2018 - 2030 (USD Million)
Chapter 7. U.S. Inflammatory Bowel Disease Treatment market: Distribution Channel Business Analysis
7.1. Distribution Channel Market Share, 2024 & 2030
7.2. Distribution Channel Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
7.4. Hospital Pharmacy
7.4.1. Hospital Pharmacy Market, 2018 - 2030 (USD Million)
7.5. Retail Pharmacy
7.5.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
7.6. Online Pharmacy
7.6.1. Online Pharmacy Market, 2018 - 2030 (USD Million)
Chapter 8. U.S. Inflammatory Bowel Disease Treatment market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2024 & 2030
8.2. Regional Market Dashboard
8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
8.4. West.
8.4.1. Key Country Dynamics
8.4.2. Target Disease Prevalence
8.4.3. Regulatory Framework
8.4.4. Reimbursement Framework
8.4.5. West U.S. Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Midwest
8.5.1. Key Country Dynamics
8.5.2. Target Disease Prevalence
8.5.3. Regulatory Framework
8.5.4. Reimbursement Framework
8.5.5. Midwest U.S. Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6. Northeast
8.6.1. Key Country Dynamics
8.6.2. Target Disease Prevalence
8.6.3. Regulatory Framework
8.6.4. Reimbursement Framework
8.6.5. Northeast U.S. Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.7. Southwest
8.7.1. Key Country Dynamics
8.7.2. Target Disease Prevalence
8.7.3. Regulatory Framework
8.7.4. Reimbursement Framework
8.7.5. Southwest U.S. Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.8. Southeast
8.8.1. Key Country Dynamics
8.8.2. Target Disease Prevalence
8.8.3. Regulatory Framework
8.8.4. Reimbursement Framework
8.8.5. Southeast U.S. Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
9.5.1. Biogen
9.5.1.1. Overview
9.5.1.2. Financial Performance
9.5.1.3. Product Benchmarking
9.5.1.4. Strategic Initiatives
9.5.2. Novartis AG
9.5.2.1. Overview
9.5.2.2. Financial Performance
9.5.2.3. Product Benchmarking
9.5.2.4. Strategic Initiatives
9.5.3. Eli Lilly and Company
9.5.3.1. Overview
9.5.3.2. Financial Performance
9.5.3.3. Product Benchmarking
9.5.3.4. Strategic Initiatives
9.5.4. UCB S.A.
9.5.4.1. Overview
9.5.4.2. Financial Performance
9.5.4.3. Product Benchmarking
9.5.4.4. Strategic Initiatives
9.5.5. Merck & Co., Inc.
9.5.5.1. Overview
9.5.5.2. Financial Performance
9.5.5.3. Product Benchmarking
9.5.5.4. Strategic Initiatives
9.5.6. Johnson & Johnson Services, Inc.
9.5.6.1. Overview
9.5.6.2. Financial Performance
9.5.6.3. Product Benchmarking
9.5.6.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviation
Table 3 U.S. inflammatory bowel disease market revenue estimates and forecast by type, 2018 - 2030 (USD Million)
Table 4 Prevalence of Crohn’s Disease in the U.S. (Per 100,000)
Table 5 Prevalence of Ulcerative Colitis in the U.S. (Per 100,000)
Table 6 U.S. inflammatory bowel disease market revenue estimates and forecast, by drug class, 2018 - 2030 (USD Million)
Table 7 Key corticosteroid drugs used in the U.S. for IBD treatment
Table 8 Key drugs with their description included in others segment
Table 9 U.S. inflammatory bowel disease market revenue estimates and forecast, by route of administration, 2018 - 2030 (USD Million)
Table 10 Key oral medications approved for IBD
Table 11 U.S. inflammatory bowel disease market revenue estimates and forecast by distribution channel, 2018 - 2030 (USD Million)
Table 12 Key players undertaking mergers and acquisitions
Table 13 Key players undertaking partnerships and collaborations
Table 14 Key players undertaking new product launches
Table 15 Other strategies taken up by the market players
List of Figures
Fig. 1 U.S. inflammatory bowel disease market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market snapshot
Fig. 10 Type and drug class segment snapshot
Fig. 11 Route of administration and distribution channel segment snapshot
Fig. 12 Competitive landscape snapshot
Fig. 13 Parent market value, 2024 (USD billion)
Fig. 14 Market dynamics
Fig. 15 Porter’s five forces analysis
Fig. 16 PESTEL analysis
Fig. 17 U.S. Inflammatory bowel disease market: Type outlook and key takeaways
Fig. 18 U.S. Inflammatory Bowel Disease market: Type movement analysis
Fig. 19 Crohn's disease market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Ulcerative colitis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 U.S. inflammatory bowel disease market: Drug class outlook and key takeaways
Fig. 22 U.S. inflammatory bowel disease market: Drug class movement analysis
Fig. 23 Aminosalicylates market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Corticosteroids market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 TNF inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 IL inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Anti-integrin market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 JAK inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 U.S. inflammatory bowel disease market: Route of administration outlook and key takeaways
Fig. 31 U.S. inflammatory bowel disease market: Route of administration movement analysis
Fig. 32 Oral market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 U.S. inflammatory bowel disease market: Distribution channel outlook and key takeaways
Fig. 35 U.S. inflammatory bowel disease market: Distribution channel movement analysis
Fig. 36 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Market participant categorization
Fig. 40 Company heat map analysis
Fig. 41 Strategic framework
